Northwest Biotherapeutics, Inc.
NWBO
$0.2984
$0.01525.37%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -83.78M | -69.53M | -73.68M | -70.26M | -62.60M |
| Total Depreciation and Amortization | 2.04M | 1.96M | 1.93M | 1.84M | 1.73M |
| Total Amortization of Deferred Charges | 2.48M | 1.98M | 2.16M | 2.40M | 2.37M |
| Total Other Non-Cash Items | 12.24M | 8.89M | 10.87M | 11.59M | 8.55M |
| Change in Net Operating Assets | 10.00M | 2.90M | -767.00K | -362.00K | -3.70M |
| Cash from Operations | -57.02M | -53.79M | -59.48M | -54.80M | -53.64M |
| Capital Expenditure | -1.01M | -1.35M | -1.62M | -2.34M | -3.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.01M | -1.35M | -1.62M | -2.34M | -3.44M |
| Total Debt Issued | 34.22M | 32.56M | 39.30M | 30.45M | 33.35M |
| Total Debt Repaid | -1.43M | -1.23M | -426.00K | -284.00K | -385.00K |
| Issuance of Common Stock | 15.75M | 11.65M | 4.54M | 2.78M | 1.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 8.20M | 11.63M | 16.51M | 14.57M | 13.33M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.00K | 643.00K | 843.00K | 4.75M | 4.75M |
| Cash from Financing | 56.79M | 55.26M | 60.76M | 52.26M | 52.76M |
| Foreign Exchange rate Adjustments | 1.30M | -3.27M | 1.79M | 1.17M | -523.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.00K | -3.16M | 1.46M | -3.71M | -4.84M |